746403_1 SGD/MG/nai* August 30, 2007 SEP 0 4 2007

PATENT APPLICATION DOCKET NO.: 2478.2018-001

THE UNITED STATES PATENT AND TRADEMARK OFFICE

	TRADE	MANUAL CONTROL OF THE	O I KADEMIA	ARR OFFICE
Applicar	nt:	John M. Williams		
Applicat	ion No.:	10/719,055	Group:	1614
Filed:		November 21, 2003	Examiner:	Shirley V. Gembeh
Confirm	ation No.:	9135		
For:		Inhibition of Chronic Tissue Transpl	lant Rejection	
	••	CERTIFICATE OF MAILING OR T I hereby certify that this correspondence is being States Postal Service with sufficient postage as First envelope addressed to Commissioner for Patents, P VA 22313-1450, or is being facsimile transmitted and Trademark Office on: R130/67 Date Signorer Typed or printed name of person signorer Sign	g deposited with the Ust Class Mail in an P.O. Box 1450, Alexa to the United States Fundante	Jnited Indria,
. /	CHIPPI	EMENTAL INFORMATION DIS	CI OSLIDE S	TATEMENT
	SUITE	DIVIDING THE ONLY TO THE	CLOSCICES	TATEMENT
Commis P.O. Box	p Amendmer sioner for Par k 1450 ria, VA 2231	tents		
Sir:				
This Info	ormation Disc	closure Statement is submitted:		
(\ na	ational stage in an i	1.97(b), or ne following time periods: three months of filing nation international application; or before the mailing date of a sa Request for Continued Examination).	al application (other first office action on	than a CPA) or date of entry of the the merits in a non-provisional application,
	under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)			
u	under 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)			
	nder 37 CFR Applicant requested after payment	uests that the IDS and cited reference	(s) be placed i	n the application file.

09/04/2007 SSITHIB1 00000036 10719055

Statement Under 37 CFR 1.97(e)

	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
Statem	nent Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
\boxtimes	Enclosed herewith is a Listing of References:
•	Copies of the cited references are enclosed.
	Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
	Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [OPTIONAL [The earlier application contains copies of the cited references.]
	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
	The "concise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:
	the explanation provided on the attached sheet.
	the explanation provided in the Specification.
	submission of the enclosed International Search Report.
	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
	the enclosed English language abstract.

		cant requests that the following the lower than the stamp "Non-Published ID."		
Examiner's Initials				
		U.S. Patent Application No.	[], by [inventor(s)], filed	[], Docket No.: []
		U.S. Patent Application No.	[], by [inventor(s)], filed	[], Docket No.: []
		U.S. Patent Application No.	[], by [inventor(s)], filed	[], Docket No.: []
		Examiner	Date	
		except any application filed	application, including the cu on or after June 30, 2003, w per (IFW) system and is avai	hich has been scanned into
		= -		nrrent claims, is enclosed, on No. [], to which priority
		r is requested to return a copy re considered with the next o		applications indicating which
It is re	quested	that the information disclose	d herein be made of record i	n this application.
Metho	d of pa	yment:		
\boxtimes		ck for the fee noted above is companying Reply. A copy of		
	Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.			
\boxtimes	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.			
		Re	spectfully submitted,	
		By Mi Re Te	chael Gottselig, Ph.D. gistration No. 57,941 lephone: (978) 341-0036 esimile: (978) 341-0136	L& REYNOLDS, P.C.

Concord, MA 01742-9133
Dated: 8/30/2007

Substitute for form 1449B/PTO		ATTORNEY DOCKET NO. 2478.2018-001 FIRST NAMED INVENTOR		APPLICATION NO. 10/719,055 FILING DATE	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT					
IN AN APPLICATION OIPE	John M. Willia		November 21,		
LISTING OF REFERENCES	EXAMINER	CONFI	RMATION NO.	GROUP	
August 30, 2007 SEP 0 4 200	Shirley V. Gen	nbeh 9135		1614	
(Use several sheets if necessar)	9 /				

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	C1	Retrieved from internet, www4.od.nih.gov/biomarkers/b9.htm, Cytokine Gene Polymorphisms, pages 4 and 5, July 31, 2007.			
	C2	Chalasani, Geetha, et al., "The Allograft Defines the Type of Rejection (Acute versus Chronic) in the Face of an Established Effector Immune Response," The Journal of Immunology, 172: 7813-7820 (2004).			
	C3	Goodman, J. and Mohanakumar T., "Chronic rejection: failure of immune regulation," Front. BioSci., Sep 1;8:s838-44 (2003).			
	C4				
	C5				
	C6				
	C7				
	C8				
	C9				
	C10				
	C11				
	C12				
	C13				
,	C14				
	C15				
	C16				
	C17				

EXAMINER	DATE CONSIDERED	